非瓣膜病心房颤动伴冠心病患者抗栓治疗研究进展

The Progress of Antithrombotic Treatment in Patients of Non-valvular Atrial Fibrillation with Coronary Heart Disease

临床上最常见需要抗栓治疗包括抗凝和抗血小板的疾病是心房颤动合并冠状动脉内支架植入和/或急性冠脉综合征,但是如果按照房颤和冠状动脉内支架植入或急性冠脉综合征要求进行常规剂量抗栓药物会增加出血发生率,但减少任何一种抗凝或抗血小板药物又可能增加卒中或栓塞事件的发生,这类患者的最佳治疗方案仍未达成共识。现对目前国际、国内针对此类患者的抗栓治疗的最新指南及实验研究等进行综述。

The common disease needed antithrombotic therapy including anticoagulation and antiplatelet therapy is atrial fibrillation patient accompanied with percutaneous coronary intervention and/or acute coronary syndrome, however, the incidence of bleeding may increase according to the conventional dose with the therapy of atrial fibrillation and percutaneous coronary intervention or acute coronary syndrome, and embolic event may increase in case that there is absence of any of one anticoagulation or antiplatelet drugs, so optimal treatment is controversial. Overview is on present research situation about antithrombotic therapy on these patients.